Sulfasalazine(TEN)

## Report on Sulfasalazine Adverse Drug Reaction Labeling Amendment **1. Executive Summary:** This report analyzes a directive issued by the Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), Government of India, regarding the drug Sulfasalazine. The directive mandates the inclusion of Toxic Epidermal Necrolysis (TEN) as an adverse drug reaction in the label/package insert/promotional literature of Sulfasalazine formulations marketed in India. This amendment aims to enhance patient safety by providing more comprehensive information to healthcare professionals and patients regarding potential risks associated with the drug. **2. Introduction:** The purpose of this report is to provide information regarding a directive from the CDSCO concerning Sulfasalazine. This report analyzes the provided text to understand the reason for the change. **3. Policy Overview:** * This is an amendment to existing policy regarding the labeling and prescribing information for Sulfasalazine. * **Core Objective:** To incorporate Toxic Epidermal Necrolysis (TEN) as an adverse drug reaction in the prescribing information leaflet (PIL) of Sulfasalazine to promote patient safety. **4. Background and Rationale:** This amendment is driven by the identification of a potential safety concern related to Sulfasalazine: the risk of Toxic Epidermal Necrolysis (TEN). The National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI) identified this potential risk based on Adverse Drug Reaction (ADR) reports. The Subject Expert Committee (SEC) - Gastroenterology & Hepatology further deliberated on this finding, leading to the recommendation to include TEN as a known adverse drug reaction on product labeling. This amendment appears to be designed to ensure patients and healthcare providers are aware of this risk. **5. Key Provisions / Changes:** This directive introduces a specific change to the labeling requirements for Sulfasalazine. * **Original Policy Component Affected:** This directive affects the information presented in the label/package insert/promotional literature of Sulfasalazine. * **New Rule/Provision:** Manufacturers of Sulfasalazine formulations are now *required* to include Toxic Epidermal Necrolysis (TEN) as an adverse drug reaction on the label, package insert, and promotional literature of the drug. * **Effect of Change:** The effect of this change is to provide more complete information about potential risks associated with Sulfasalazine, specifically highlighting the possibility of TEN. This allows healthcare providers and patients to make more informed decisions regarding the use of the drug. **6. Target Audience and Stakeholders:** The primary target audience includes: * Manufacturers of Sulfasalazine formulations in India. * State/UT Drugs Controllers who oversee these manufacturers. * Healthcare professionals (prescribers, pharmacists) who prescribe and dispense Sulfasalazine. * Patients who use Sulfasalazine. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** * CDSCO (Directorate General of Health Services, Government of India) is the issuing and overseeing body. * State/UT Drugs Controllers are responsible for directing manufacturers under their jurisdiction to comply with the directive. * NCCPvPI (functioning at IPC Ghaziabad) is involved in pharmacovigilance and ADR reporting. * **Timelines/Procedures:** The directive requests that manufacturers be directed to make the changes. It also requests that the actions taken be reported back to the CDSCO. No specific deadlines for compliance are mentioned in the provided text. The implication is that prompt action is expected. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is: * **Increased awareness:** Patients and healthcare providers will be more aware of the risk of TEN associated with Sulfasalazine. * **Improved patient safety:** Informed decision-making by prescribers and patients may lead to earlier detection and management of TEN, potentially reducing its severity and improving patient outcomes. * **More informed risk-benefit assessments:** Healthcare professionals will be better equipped to assess the risks and benefits of using Sulfasalazine for individual patients, especially those with predisposing factors for TEN. **9. Conclusion:** The CDSCO's directive to include Toxic Epidermal Necrolysis (TEN) as an adverse drug reaction on Sulfasalazine product labeling is a significant amendment aimed at improving patient safety. This change ensures that vital risk information is readily available to healthcare professionals and patients, allowing for more informed decisions regarding the use of Sulfasalazine. While the text does not specify timelines for the change, prompt action by manufacturers under the direction of the State/UT Drugs Controllers is implied.

Key Entities Referenced